Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04147078
Recruiting Phase 1

Personalized DC Vaccine for Postoperative Cancer

NCT04147078 · tracked via the Priya Life Science China tracker
Sponsor
Sichuan University
Phase
Phase 1
Started
2019-06-01
Last updated
2025-02-28

Condition(s) studied

Gastric CancerHepatocellular CarcinomaNon-Small-Cell Lung CancerColon Rectal Cancer

Investigational drug(s) / intervention(s)

DC vaccine subcutaneous administration

DC vaccine subcutaneous administration: subcutaneous administration

Study summary

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation * Anticipated life time \> 3month * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Adequate organ functions Exclusion Criteria: * Any evidence of tumor metastasis or co-existing malignant disease * Tumor emergency * Abnormal coagulation condition * Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection * Concomitant tumors * Immunological co-morbidities

Primary outcome measure(s)

  • Disease-free Survival (DFS) — Up to 5 years
    Defined as the time from the surgery to the first documented disease recurrence or death (by any cause), whichever occurs first

Trial sites (1)

FacilityCityRegionStatus
Qiu Li Chengdu Sichuan Recruiting

More Sichuan University trials in China

Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study Starting soon
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC Starting soon
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study Starting soon
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC Active, not recruiting
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma Recruiting

Other trials for the same condition

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore Recruiting
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) Active, not recruiting
Study for AZD4360 in Participants With Advanced Solid Tumours Active, not recruiting
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04147078 on ClinicalTrials.gov ↗ ← All trials in China